Microalbuminuria Screening as Reliable Marking for Diabetes Gaining Prominence

San Francisco, California, July 25, 2017: The growing significance of microalbuminuria as reliable and an independent predictor of cardiovascular disease and progressive renal disease has led to the constant evolution of the market. The rapidly increasingly burden of cardiovascular diseases worldwide and the rise in associated mortality and morbidity among adults, especially in developed nations, is a crucial trend boosting the microalbuminuria market. A new report penned by TMR Research, titled “Microalbuminuria Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017– 2025”, offers an elaborate assessment of various factors and trends influencing the growth of the market.

The research offers in-depth insights into the share and size of major trends, emerging diagnostics and therapies, research and development activities, recent technological advancements, and competitive landscape in various regions. The study tracks key clinical developments and studies related to albuminuria screenings in various populations groups and evaluates their impact on the emerging market dynamics. It also highlights major screening methods developed by prominent players.

The increasing clinical relevance of microalbuminuria as a key risk factor for the development of cardiovascular diseases and as a reliable marker of systemic endothelial dysfunction in general populations are significant factors catalyzing the market.

The relevance of microalbuminuria screening has gained particular significance in high-risk populations, those afflicted with systemic diseases such as diabetes and hypertension. This has clearly boosted the microalbuminuria market. In addition, the growing prevalence of prevalence of obesity, type 2 diabetes, and metabolic syndrome in children is a crucial trend catalyzing the growth of the market. In recent years, the screening for microalbuminuria among pediatric populations has gained some traction in the detection and prevention of cardiovascular disorders. This is expected to catalyze the microalbuminuria market growth.

In recent years, establishing of a close link between systemic endothelial dysfunction and vascular diseases have stimulated researches in the market. Furthermore, evaluation of the pharmacologic and non-pharmacologic strategies in mitigating the key risk factors such as hypertension and dyslipidemia in high-risk populations bodes well for the market. In addition, increasing initiatives by clinicians in screening for microalbuminuria among diabetic populations is anticipated to accentuate the market in the coming years. Recent advances in the currently available laboratory testing methods and semi-quantitative tests are anticipated to open up exciting opportunities for players in the microalbuminuria market.

Regionally, currently North America is a prominent market for microalbuminuria, with a substantial demand for the screening and therapies coming from the countries such as the U.S. and Canada. Several studies being conducted in these nations on understanding the pathophysiological mechanism for the condition and initiatives undertaken by national health agencies on early drug interventions are the key factors boosting the regional market. The soaring morbidity of cardiovascular disease in the U.S. is expected to open up lucrative growth avenues for market players.

Prominent players operating in the microalbuminuria market include Daiichi Sankyo Company, Limited, AbbVie Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company, Ltd., Steno Diabetes Center A/S, Alfa Wassermann S.p.A, Sanofi S.A., and Novartis International AG.